These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 33840294)

  • 1. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.
    Teo SP
    J Pharm Pract; 2022 Dec; 35(6):947-951. PubMed ID: 33840294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
    Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
    Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021.
    Tenforde MW; Patel MM; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Botros M; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Lindsell CJ; Hart KW; Zhu Y; Naioti EA; Adams K; Lewis NM; Surie D; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):118-124. PubMed ID: 35085218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.
    Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M
    Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
    Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights.
    Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ
    Interdiscip Sci; 2021 Jun; 13(2):344-347. PubMed ID: 34021862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.
    Pawlowski C; Lenehan P; Puranik A; Agarwal V; Venkatakrishnan AJ; Niesen MJM; O'Horo JC; Virk A; Swift MD; Badley AD; Halamka J; Soundararajan V
    Med; 2021 Aug; 2(8):979-992.e8. PubMed ID: 34223401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine.
    Islam N; Sheils NE; Jarvis MS; Cohen K
    Nat Commun; 2022 May; 13(1):2377. PubMed ID: 35501319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time and cost of administering COVID-19 mRNA vaccines in the United States.
    Yarnoff B; Bodhaine S; Cohen E; Buck PO
    Hum Vaccin Immunother; 2021 Nov; 17(11):3871-3875. PubMed ID: 34613860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain).
    Chico-Sánchez P; Gras-Valentí P; Algado-Sellés N; Jiménez-Sepúlveda N; Vanaclocha H; Peiró S; Burgos JS; Berenguer A; Navarro D; Sánchez-Payá J;
    Prev Med; 2022 Oct; 163():107237. PubMed ID: 36057393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022.
    Wallace M; Moulia D; Blain AE; Ricketts EK; Minhaj FS; Link-Gelles R; Curran KG; Hadler SC; Asif A; Godfrey M; Hall E; Fiore A; Meyer S; Su JR; Weintraub E; Oster ME; Shimabukuro TT; Campos-Outcalt D; Morgan RL; Bell BP; Brooks O; Talbot HK; Lee GM; Daley MF; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(11):416-421. PubMed ID: 35298454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.